Xinhua News Agency, Beijing (Reporter Zhaohui Zhang) — Huadong Medicine Co., Ltd. announced on December 30 that its wholly-owned subsidiary, Huadong Medicine, has reached a strategic cooperation with Synerk Pharmaceutical Technology (Suzhou) Co., Ltd. ("Synerk"). Both parties will jointly develop the small nucleic acid (siRNA) candidate drug SNK-2726 targeting angiotensinogen (AGT) for the treatment of hypertension. Huadong Medicine has obtained the exclusive option for the development, registration, production, and commercialization of this drug in Greater China.
SNK-2726, currently in the preparation stage for a new drug clinical application submission, is an siRNA drug developed by Synerk. According to the cooperation agreement, both parties will jointly advance the development of SNK-2726 to a certain stage. Meanwhile, Huadong Medicine will obtain an exclusive option and can pay an exercise fee in the future to acquire the exclusive rights to develop, register, manufacture, and commercialize SNK-2726 in Greater China. After Huadong Medicine exercises the option, Synerk will also be entitled to subsequent R&D milestone payments and sales milestone payments, as well as tiered royalties based on net sales after commercialization.
Public information shows that Synerk is a biopharmaceutical company focused on developing RNA-targeted therapies. It aims to build an RNA-targeted treatment company by developing products with the potential to become "first-in-class" or "best-in-class" to treat diseases that are difficult to cure with existing therapies.
Proofread by Mu Xiangtong